官方服务：
资源简介：
Whole genome resequencing data of imatinib sensitive and resistent tumor of one DFSP patient.
应用场景：
创建时间：
2013-05-12
相关数据集
Genomic profiling of Imatinib resistance in CD34+ cell populations from chronic myeloid leukaemia patients using Agilent-014698 Whole Human Genome 105K microarrays.. Homo sapiens
To ascertain genomic alterations associated with Imatinib resistance in chronic myeloid leukaemia, we performed high resolution genomic analysis of CD34+ cells from 25 Imatinib (IM) resistant and 11 r
NIAID Data Ecosystem110
Gene expression analysis of chronic myeloid leukemic stem cells and progenitor cells from untreated and imatinib-treated CML-like mice
To understand gene expression signatures of CML stem cells underlying imatinib-resistance, we compared transcriptomes of CML stem and progenitor cells from vehicle and imatinib-treated CML mice, respe
NIAID Data Ecosystem70
Expression profile of Imatinib treated BAF3 -BCR-ABL cells. Mus musculus
BAF3 cells harboring constitutively expressing BCR-ABL were grown with or without IL-3 supplement and treated with Imatinib and live cells from the IL-3 and without IL-3 were sorted by FACS. Overall d
NIAID Data Ecosystem50
Gene expression profile of K562 human leukemia cell line after imatinib treatement
K562 cells when grown with erythropeitin do not respond to Imatinib. Here we are comparing the gene expression profile from imatinib resistant and sensitive cells. K562 cells when grown with erythrope
NIAID Data Ecosystem80
Chronic Myeloid Leukemia Patients Sensitive and Resistant to Imatinib Treatment Show Different Metabolic Responses
The BCR-ABL tyrosine kinase inhibitor imatinib is highly effective for chronic myeloid leukemia (CML). However, some patients gradually develop resistance to imatinib, resulting in therapeutic failure
NIAID Data Ecosystem60
